Rapport Therapeutics (NASDAQ:RAPP - Get Free Report)'s stock price was down 5.6% during mid-day trading on Friday . The company traded as low as $16.05 and last traded at $15.82. Approximately 11,780 shares changed hands during trading, a decline of 88% from the average daily volume of 97,091 shares. The stock had previously closed at $16.75.
Rapport Therapeutics Stock Performance
The business has a 50-day simple moving average of $17.08 and a two-hundred day simple moving average of $20.27.
Hedge Funds Weigh In On Rapport Therapeutics
Several hedge funds have recently modified their holdings of RAPP. Values First Advisors Inc. acquired a new position in shares of Rapport Therapeutics during the 3rd quarter worth approximately $31,000. BNP Paribas Financial Markets acquired a new stake in Rapport Therapeutics in the third quarter valued at $34,000. The Manufacturers Life Insurance Company grew its position in shares of Rapport Therapeutics by 2.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 77,344 shares of the company's stock valued at $1,584,000 after acquiring an additional 1,828 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Rapport Therapeutics in the 4th quarter valued at about $34,000. Finally, Barclays PLC lifted its stake in Rapport Therapeutics by 36.8% in the 3rd quarter. Barclays PLC now owns 12,863 shares of the company's stock valued at $264,000 after purchasing an additional 3,463 shares during the last quarter.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Further Reading
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
